What is Keytruda (Pembrolizumab)?
Pembrolizumab belongs to the group of the immunotherapy drugs — type of medicine that can treat certain cancers by influencing on patient's immune system. It blocks a protective mechanism of cancer cells and allows the immune system to destroy them. Monoclonal antibody to programmed cell death-1 protein (PD-1) blocks the interaction between PD-1 and its ligands — PD-L1 and PD-L2.
Keytruda prices are specified in this listing. Submit a request to get a personalized quote.
Is Pembrolizumab FDA approved?
On May 23, 2017, the U.S. Food and Drug Administration granted for Pembrolizumab (Keytruda) an accelerated approval — faster approval of drugs for serious conditions that fill an unmet medical need. FDA allowed prescribing immunotherapy new drug to treat patients whose cancers have a specific genetic feature (biomarker).
What are Keytruda success rates?
During the clinical trials of Keytruda, the following indicators were achieved:
|
Period |
The survival rate of patients with 3-4 stages of cancer |
|
6 month |
92% |
|
1 year |
69% |
|
1,5 years |
62% |
|
2 years |
58% |
Who produces Keytruda?
The manufacturer is Merck & Co., Inc. — an American pharmaceutical company and one of the largest pharmaceutical companies in the world. Research performed at Merck has led to FDA approval of 63 new drugs. Company has developed more new drugs than any other company in the USA.